New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

Table 2 Vorinostat in combination trials

HDACI	Other agent	Disease	Dosage	Phase	Pts No	Response	Reference
Vorinostat	capecitabine	Solid tumors	VOR:300–400 mg/d PO CAP:750–1000 mg bid PO	I	28	CR: 3% PR: 10% SD: 64%	[33]
Vorinostat	bevacizumab	kidney cancer	VOR:200 mg BID × 14 d PO BEV:15 mg/kg, q21div	I	8	SD: 42%	[27]
Vorinostat	bexarotene	CTCL	VOR:300–400 mgqdPOq28d BEX:150–300 mg/m²qdq28d	I	19	CR: 5% PR: 15% SD: 63%	[28]
Vorinostat	tamoxifen	breast cancer	VOR:400 mg/d ×21d PO T AM:20 mg/d PO	II	19	CR: 5% PR: 15%	[32]
Vorinostat	Gemcitabine Carboplatin/Cisplatin	NSCLC	VOR:300–400 mgqdPOx7d GEM:1000–1250 mg/m², ivd3, 10 C BP:5.0AUC, iv/CDDP:75 mg/m², iv d3	I	12	PR: 57% SD: 28%	[38]
Vorinostat	13-cis-retinoid acid	Pediatric CNS, solid tumors	VOR:180–230 mg/m² po qd 13cRA: 80 mg/m²po bid	I	13	MTD: VOR 180 mg/m²/d × 4/w 13cRA: 80 mg/m²bid	[39]
Vorinostat	Carboplatin Paclitaxel	solid tumors	VOR:400–600 mg/d PO q21d C BP:6.0 AUC, iv PTX:200 mg/m², iv	I	28	PR: 44% SD: 28%	[34]
Vorinostat	bortezomib	MM	VOR:100–400 mg PO d4–11 VEL:1.3 mg/m² IV d1, 4, 8 and 11	I	23	MTD: VOR 400 mg d 4–11;VEL1.3 mg/m²d1, 4, 8, 11.	[25]

VEL: bortezomib; CR: complete responses; PR: partial response; SD: stable disease. MTD: maximal tolerated dose;

ISSN: 1756-8722